{"id":18129,"date":"2021-12-13T09:09:06","date_gmt":"2021-12-13T17:09:06","guid":{"rendered":"https:\/\/marketdepth.com\/?p=18129"},"modified":"2021-12-13T09:09:07","modified_gmt":"2021-12-13T17:09:07","slug":"pfizer-to-acquire-arena-pharmaceuticals-in-a-6-7b-deal","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/pfizer-to-acquire-arena-pharmaceuticals-in-a-6-7b-deal\/","title":{"rendered":"Pfizer to Acquire Arena Pharmaceuticals in a $6.7B Deal"},"content":{"rendered":"\n
Pfizer Inc. (NYSE: PFE) today announced that it has entered into a definitive agreement to acquire Arena Pharmaceuticals Inc. (NASDAQ: ARNA).<\/p>\n\n\n\n
Shares of Arena Pharmaceuticals Inc. (NASDAQ: ARNA) surged over 86% in premarket trading, as shares of Pfizer Inc. (NYSE: PFE)\u00a0 gained 1.2%.<\/p>\n\n\n\n
The all-cash transaction has a total equity value of approximately $6.7 billion, with Pfizer to acquire all the outstanding shares of Arena for $100 per share. The proposed acquisition offers a \u201cpotentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases,\u201d according <\/a>to the Pfizer press release.<\/p>\n\n\n\n \u201cThe proposed acquisition of Arena complements our capabilities and expertise in Inflammation and Immunology, a Pfizer innovation engine developing potential therapies for patients with debilitating immuno-inflammatory diseases with a need for more effective treatment options.\u201d<\/p>Mike Gladstone, Global President & General Manager, Pfizer Inflammation and Immunology<\/cite><\/blockquote>\n\n\n\n Arena\u2019s development program includes development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology as well as two development-stage cardiovascular assets, temanogrel and APD418.<\/p>\n\n\n\n \u201cWe\u2019re delighted to announce Pfizer\u2019s proposed acquisition of Arena, recognizing Arena\u2019s potentially best in class S1P molecule and our contribution to addressing unmet needs in immune-mediated inflammatory diseases.\u201d<\/p>Amit D. Munshi, President and Chief Executive Officer of Arena<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"Pfizer Inc. (NYSE: PFE) today announced that it has entered into a definitive agreement to acquire Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Surged 86% Shares of Arena Pharmaceuticals Inc. (NASDAQ: ARNA) surged over 86% in premarket trading, as shares of Pfizer Inc. (NYSE: PFE)\u00a0 gained 1.2%. All-Cash Transaction The all-cash transaction has a total equity value… View Article<\/a>","protected":false},"author":3,"featured_media":18130,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[10,31,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\n